Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HINT1 | P49773 | 2/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101375 | 0.90 | ADORA3 (0.53) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL12758342 | 0.88 | HINT1 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL12151803 | 0.88 | HINT1 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL1374868 | 0.88 | HINT1 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL3734057 | 0.88 | ADORA3 (0.51) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL3427138 | 0.88 | ADORA3 (0.50) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL18490626 | 0.87 | ADORA3 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL28911222 | 0.87 | HPGD (0.54) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL3437184 | 0.86 | NT5E (0.51) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL29771263 | 0.86 | HINT1 (0.51) | ADORA3HPGDHINT1NT5ESTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325426-A1 | POLYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION | KYOWA KIRIN CO., LTD. (JP) | 2024-10-03 | — | — | US | disclosed |
| US-20240300992-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2024-09-12 | — | — | US | disclosed |
| EP-4365288-A1 | POLYNUCLEOTIDE AND MEDICINAL COMPOSITION | Kyowa Kirin Co., Ltd. (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-20240034748-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | GERON CORP (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230089101-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | GERON CORP (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230073999-A1 | POLYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-03-09 | — | — | US | disclosed |
| WO-2023277168-A1 | POLYNUCLEOTIDE AND MEDICINAL COMPOSITION | 協和キリン株式会社 | 2023-01-05 | — | — | WO | disclosed |
| EP-4082579-A1 | POLYNUCLEOTIDE AND MEDICINAL COMPOSITION | National University Corporation Tokai National Higher Education and Research System (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325426-A1 | POLYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION | RNGTT, RNMT, NT5C | ADORA3 430/4885HPGD 4222/4885HINT1 412/4885 |
| US-20230089101-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | NT5C3B, RNMT, UMPS | ADORA3 236/4885HPGD 1724/4885HINT1 319/4885 |
| US-20240034748-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | NT5C3B, RNMT, UMPS | ADORA3 236/4885HPGD 1724/4885HINT1 319/4885 |
| US-20240300992-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | NT5C3B, RNMT, UMPS | ADORA3 236/4885HPGD 1724/4885HINT1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.